News
PBM
1.760
-2.76%
-0.050
Weekly Report: what happened at PBM last week (1124-1128)?
Weekly Report · 5d ago
Psyence Biomedical announces psilocybin longevity research program
TipRanks · 11/25 12:15
Psyence BioMed Launches Psilocybin Longevity Research Program
Reuters · 11/25 12:11
Weekly Report: what happened at PBM last week (1117-1121)?
Weekly Report · 11/24 10:32
Psyence BioMed Expands Ibogaine Operations in Africa with Strategic Investment
TipRanks · 11/21 22:53
Psyence BioMed Takes Minority Stake in PsyLabs to Boost African Ibogaine Operations
Reuters · 11/21 22:18
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 11/21 12:05
Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga · 11/21 09:41
Psyence Biomedical Reports Strong Financial Growth in Latest Interim Results
TipRanks · 11/20 21:39
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 11/20 17:05
Psychedelic: Clearmind reports results from first cohort in AUD trial
TipRanks · 11/20 17:05
Psyence Biomedical establishes supply of high-potency iboga bark
TipRanks · 11/20 12:11
Psyence Secures Long-Term Supply Of Plant-Based Drug Ingredient For Addiction Treatment Research, Moves Closer To Clinical Trials With New Source Of Ibogaine For Substance Use Therapies
Benzinga · 11/20 12:10
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 11/20 12:05
Weekly Report: what happened at PBM last week (1110-1114)?
Weekly Report · 11/17 10:33
Psychedelic: Atai Beckley, Cybin report quarterly earnings
TipRanks · 11/13 16:31
Psyence Biomedical establishes ibogaine operations in Africa
TipRanks · 11/12 12:25
Psyence BioMed Expands Through PsyLabs, Establishing Exclusive Public Market Presence In Africa For Ibogaine & Psilocybin Development
Benzinga · 11/12 12:12
Psyence BioMed Invests in PsyLabs to Establish Ibogaine Operations in Africa
Reuters · 11/12 12:00
PSYENCE BIOMED ESTABLISHES IBOGAINE OPERATIONS IN AFRICA THROUGH STRATEGIC INVESTMENT IN PSYLABS
Reuters · 11/12 12:00
More
Webull provides a variety of real-time PBM stock news. You can receive the latest news about Psyence Biomedical Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.